NCT02962388 - The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

June 28, 2021

Study Completion Date

June 28, 2021

Conditions

Essential Thrombocythemia

Interventions

DRUG

Anagrelide

Anagrelide in the study, according to the investigator decision fom day 1 to 48 months

DRUG

Ruxolitinib (JAKAVI®)

Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months

DRUG

IFNα/ PegIFNα

IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months

Trial Locations (1)

37044

FILO, Tours